|
1
|
Shivarov V and Bullinger L: Expression
profiling of leukemia patients: Key lessons and future directions.
Exp Hematol. 42:651–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ross K, Gillespie-Twardy AL, Agha M,
Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, et
al: Intensive chemotherapy in patients aged 70 years or older newly
diagnosed with acute myeloid leukemia. Oncol Res. 22:85–92. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang ES: Treating acute myeloid leukemia
in older adults. Hematology (Am Soc Hematol Educ Program).
2014:14–20. 2014.
|
|
4
|
Mayer J, Arthur C, Delaunay J, Mazur G,
Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, et
al: Multivariate and subgroup analyses of a randomized,
multinational, phase 3 trial of decitabine vs treatment choice of
supportive care or cytarabine in older patients with newly
diagnosed acute myeloid leukemia and poor- or intermediate-risk
cytogenetics. BMC Cancer. 14:692014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kantarjian HM, Thomas XG, Dmoszynska A,
Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R,
Cermak J, et al: Multicenter, randomized, open-label, phase III
trial of decitabine versus patient choice, with physician advice,
of either supportive care or low-dose cytarabine for the treatment
of older patients with newly diagnosed acute myeloid leukemia. J
Clin Oncol. 30:2670–2677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dombret H, Seymour JF, Butrym A,
Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC,
Candoni A, et al: International phase 3 study of azacitidine vs
conventional care regimens in older patients with newly diagnosed
AML with >30% blasts. Blood. 126:291–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou T, Hasty P, Walter CA, Bishop AJ,
Scott LM and Rebel VI: Myelodysplastic syndrome: An inability to
appropriately respond to damaged DNA? Exp Hematol. 41:665–674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Einbond LS, Shimizu M, Nuntanakorn P,
Seter C, Cheng R, Jiang B, Kronenberg F, Kennelly EJ and Weinstein
IB: Actein and a fraction of black cohosh potentiate
antiproliferative effects of chemotherapy agents on human breast
cancer cells. Planta Med. 72:1200–1206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Einbond LS, Mighty J, Redenti S and Wu HA:
Actein induces calcium release in human breast cancer cells.
Fitoterapia. 91:28–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yue GGL, Xie S, Lee JKM, Kwok HF, Gao S,
Nian Y, Wu XX, Wong CK, Qiu MH and Lau CB: New potential beneficial
effects of actein, a triterpene glycoside isolated from Cimicifuga
species, in breast cancer treatment. Sci Rep. 6:352632016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang ZC and Ma J: Actein enhances TRAIL
effects on suppressing gastric cancer progression by activating
p53/caspase-3 signaling. Biochem Biophys Res Commun. Nov
30–2016.Epub ahead of print. View Article : Google Scholar
|
|
12
|
Einbond LS, Shimizu M, Ma H, Wu HA,
Goldsberry S, Sicular S, Panjikaran M, Genovese G and Cruz E:
Actein inhibits the Na+-K+-ATPase and
enhances the growth inhibitory effect of digitoxin on human breast
cancer cells. Biochem Biophys Res Commun. 375:608–613. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin MW, Wu CT, Shih JY, Chang YL and Yang
PC: Clinicopathologic characteristics and prognostic significance
of EGFR and p53 mutations in surgically resected lung
adenocarcinomas ≤2 cm in maximal dimension. J Surg Oncol.
110:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Wang L, Zheng X, Liu G, Wang Y, Lai
X and Li J: Positive expression of p53, c-erbB2 and MRP proteins is
correlated with survival rates of NSCLC patients. Mol Clin Oncol.
1:487–492. 2013. View Article : Google Scholar
|
|
16
|
Lee JH, Katakai T, Hara T, Gonda H, Sugai
M and Shimizu A: Roles of p-ERM and Rho-ROCK signaling in
lymphocyte polarity and uropod formation. J Cell Biol. 167:327–337.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Osiak AE, Zenner G and Linder S:
Subconfluent endothelial cells form podosomes downstream of
cytokine and RhoGTPase signaling. Exp Cell Res. 307:342–353. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benitah SA, Valerón PF and Lacal JC: ROCK
and nuclear factor-kappaB-dependent activation of cyclooxygenase-2
by Rho GTPases: Effects on tumor growth and therapeutic
consequences. Mol Biol Cell. 14:3041–3054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai L, Threadgill MD, Wang Y and Li M:
Effect of poly (ADP-ribose) polymerase-1 inhibition on the
proliferation of murine colon carcinoma CT26 cells. Pathol Oncol
Res. 15:323–328. 2009. View Article : Google Scholar
|
|
20
|
Ratnam K and Low JA: Current development
of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Clin Cancer Res. 13:1383–1388. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeba Y, Matsumoto N, Watanabe M,
Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura
T and Otsubo T: The Rho kinase inhibitor fasudil is involved in
p53-mediated apoptosis in human hepatocellular carcinoma cells.
Cancer Chemother Pharmacol. 69:1545–1555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tortora G, Caputo R, Damiano V, Caputo R,
Troiani T, Veneziani BM, De Placido S, Bianco AR,
Zangemeister-Wittke U and Ciardiello F: Combined targeted
inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and
protein kinase A type I causes potent antitumor, apoptotic, and
antiangiogenic activity. Clin Cancer Res. 9:866–871.
2003.PubMed/NCBI
|
|
23
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang JY, Della-Fera MA, Rayalam S and
Baile CA: Enhanced effects of xanthohumol plus honokiol on
apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring).
16:1232–1238. 2008. View Article : Google Scholar
|
|
25
|
Roy S, Yu Y, Padhye SB, Sarkar FH and
Majumdar AP: Difluorinated-curcumin (CDF) restores PTEN expression
in colon cancer cells by down-regulating miR-21. PLoS One.
8:e685432013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mueller S, Phillips J, Onar-Thomas A,
Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD,
Weiss WA, et al: PTEN promoter methylation and activation of the
PI3K/Akt/mTOR pathway in pediatric gliomas and influence on
clinical outcome. Neurooncol. 14:1146–1152. 2012.
|
|
27
|
Liu Y, Minze LJ, Mumma L, Li XC, Ghobrial
RM and Kloc M: Mouse macrophage polarity and ROCK1 activity depend
on RhoA and non-apoptotic caspase 3. Exp Cell Res. 341:225–236.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilkes DM, Xiang L, Lee SJ, Chaturvedi P,
Hubbi ME, Wirtz D and Semenza GL: Hypoxia-inducible factors mediate
coordinated RhoA-ROCK1 expression and signaling in breast cancer
cells. Proc Natl Acad Sci USA. 111:E384–E393. 2014. View Article : Google Scholar :
|
|
29
|
Wang Y, Wang D and Guo D: miR-124 promote
neurogenic transdifferentiation of adipose derived mesenchymal
stromal cells partly through RhoA/ROCK1, but not ROCK2 signaling
pathway. PLoS One. 11:e01466462016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang JG, Li XY, Wang YZ, Zhang QD, Gu SY,
Wu X, Zhu GH, Li Q and Liu GL: ROCK is involved in vasculogenic
mimicry formation in hepatocellular carcinoma cell line. PLoS One.
9:e1076612014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng H, Luo P, Li Y, Wang C, Liu X, Ye Z,
Li C and Lou T: Simvastatin alleviates hyperpermeability of
glomerular endothelial cells in early-stage diabetic nephropathy by
inhibition of RhoA/ROCK1. PLoS One. 8:e800092013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin SC, Gou GH, Hsia CW, Ho CW, Huang KL,
Wu YF, Lee SY and Chen YH: Simulated microgravity disrupts
cytoskeleton organization and increases apoptosis of rat neural
crest stem cells via upregulating CXCR4 expression and
RhoA-ROCK1-p38 MAPK-p53 signaling. Stem Cells Dev. 25:1172–1193.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mohan S, Abdul AB, Abdelwahab SI,
Al-Zubairi AS, Sukari MA, Abdullah R, Elhassan Taha MM, Ibrahim MY
and Syam S: Typhonium flagelliforme induces apoptosis in CEMss
cells via activation of caspase-9, PARP cleavage and cytochrome c
release: Its activation coupled with G0/G1 phase cell cycle arrest.
J Ethnopharmacol. 131:592–600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu X, Zou H, Slaughter C and Wang X: DFF,
a heterodimeric protein that functions downstream of caspase-3 to
trigger DNA fragmentation during apoptosis. Cell. 89:175–184. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grütter MG: caspases: Key players in
programmed cell death. Curr Opin Struct Biol. 10:649–655. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Xu J and Gu Y: 37 1, 25 (OH) 37
1,25(OH)2D3 suppresses oxidative stress-induced microparticle
release by placental trophoblasts: Placenta and decidua. Pregnancy
Hyperens. 6:1542016. View Article : Google Scholar
|
|
38
|
Shen K, Wang Y, Zhang Y, Zhou H, Song Y,
Cao Z, Kou J and Yu B: Cocktail of four active components derived
from Sheng Mai San inhibits hydrogen peroxide-induced PC12 cell
apoptosis linked with the caspase-3/ROCK1/MLC pathway. Rejuvenation
Res. 18:517–527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li G, Zhou T, Liu L, Chen J, Zhao Z, Peng
Y, Li P and Gao N: Ezrin dephosphorylation/downregulation
contributes to ursolic acid-mediated cell death in human leukemia
cells. Blood Cancer J. 3:e1082013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peng H, Cao J, Yu R, Danesh F, Wang Y,
Mitch WE, Xu J and Hu Z: CKD stimulates muscle protein loss via
rho-associated protein kinase 1 activation. J Am Soc Nephrol.
27:509–519. 2016. View Article : Google Scholar :
|
|
41
|
Heath-Engel HM, Chang NC and Shore GC: The
endoplasmic reticulum in apoptosis and autophagy: Role of the BCL-2
protein family. Oncogene. 27:6419–6433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Levine B, Sinha S and Kroemer G: Bcl-2
family members: Dual regulators of apoptosis and autophagy.
Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Arnoult D, Parone P, Martinou JC,
Antonsson B, Estaquier J and Ameisen JC: Mitochondrial release of
apoptosis-inducing factor occurs downstream of cytochrome c release
in response to several proapoptotic stimuli. J Cell Biol.
159:923–929. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sheridan C, Delivani P, Cullen SP and
Martin SJ: Bax- or Bak-induced mitochondrial fission can be
uncoupled from cytochrome c release. Mol Cell. 31:570–585. 2008.
View Article : Google Scholar : PubMed/NCBI
|
